Efficacy and Safety of IDegLira Versus Basal-Bolus Insulin Therapy in Patients With Type 2 Diabetes Uncontrolled on Metformin and Basal Insulin; DUAL VII Randomized Clinical Trial -

Efficacy and Safety of IDegLira Versus Basal-Bolus Insulin Therapy in Patients With Type 2 Diabetes Uncontrolled on Metformin and Basal Insulin; DUAL VII Randomized Clinical Trial
Information type: Randomised controlled trials
Source: Diabetes Care
Specialities: Diabetes
Summary
RCT found that insulin degludec/liraglutide (IDegLira) fixed ratio combination was non-inferior to a basal bolus regimen for HbA1c reduction (difference -0.2 mmol/mmol). IDegLira had lower rates of symptomatic hypoglycaemia (RR 0.39, 95% CI 0.29 to 0.51).
UKMi comment

Xultophy (insulin degludec 100 units/mL and liraglutide 3.6mg/mL) is licensed for the the treatment of adults with type 2 diabetes mellitus to improve glycaemic control in combination with oral glucose-lowering medicinal products when these alone do not provide adequate glycaemic control
Related links: